Immuneering Corporation (IMRX)

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Immuneering Appoints Andrew Gengos as Chief Financial Officer

- Former CFO of Terns Pharmaceuticals to join Immuneering - - Seasoned public company CFO strengthens team with...

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer

Global pivotal Phase 3 trial will evaluate efficacy and safety of atebimetinib + modified gemcitabine/nab-paclit...

Form 8-K - Current report

Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO

- 17.3 months median overall survival in 55 first-line pancreatic cancer patients; vs. 8.5 months for standard...

Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy

- Detailed data from 55 patients to be shared in an oral presentation at the ASCO Annual Meeting on June 1...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates

- New survival data from Phase 2a clinical trial evaluating atebimetinib + mGnP in first-line metastatic...

Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting

- New data from Phase 2a clinical trial evaluating atebimetinib + mGnP in first-line pancreatic cancer will be...

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material